enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
-
Solomons PM survives attempt to oust government
-
Tech firms rally on mixed day for Asian markets, with eyes on US inflation
-
Ohtani 'unlikely' to pitch again this season, says Dodgers manager
-
World number one An sends Asian Games warning with China hat-trick
-
Driver thanks 'superhero' rival for saving him from flaming race car
-
PSG go for three in a row as Champions League returns
-
Can dogs sniff cancer? AI joins the hunt in India
-
"Super-human' Alcaraz books US Open quarter-final clash with Shelton
-
Shelton steams into US Open quarter-final clash with Alcaraz
-
ECB set to hike interest rates as Iran war flares anew
-
25 years on, America seeks to keep 9/11 memories alive
-
AI data centers are less thirsty now, tech giants say
-
'Trumpapalooza' tests Republican bet on unpopular US president
-
North Korea vows nuclear-armed navy as US ally drills open
-
Pegula tops Cirstea to reach US Open quarter-finals
-
Under-fire Labuschagne named in Australia Test squad for South Africa
-
Australians could opt out of social media algorithms under new law
-
Enjoying the moment: Alcaraz steps it up to reach US Open quarter-finals
-
Tiafoe tops Medvedev in straight sets at US Open
-
Five dead, five injured after Amazon cargo plane overshoots Miami runway
-
Zverev seeks US Open last eight as Osaka faces Rybakina
-
La Rochelle half-backs lead fightback against Toulouse
-
Alcaraz turns up heat to reach US Open quarters
-
US envoys have 'more effective proposals': Ukraine official
-
Gatti salvages Juve draw with AC Milan in Serie A
-
Defending champion Alcaraz powers into US Open quarter-finals
-
Sinayoko stars as unbeaten Paris FC down Marseille
-
Amazon cargo plane overshoots Miami runway, hits vehicles, catches fire
-
Still on top: 'Spider-Man' dominates North American box office
-
Toll from Yemen clashes passes 300 as civilians flee homes
-
Zelensky in fresh talks with US envoys: Ukraine official
-
Sabalenka books US Open quarter-final clash with Noskova
-
Noskova edges Kostyuk to reach US Open quarter-finals
-
German AfD supporters jubilant at far right's thumping win
-
Alonso urges Chelsea to learn from painful defeat at Arsenal
-
Zelensky warns war likely to continue into winter after US talks
-
Defending champion Sabalenka reaches US Open quarter-finals
-
Arsenal deliver statement fightback to end Chelsea's flying start
-
Minnows Augsburg sink Frankfurt to top Bundesliga table
-
Leclerc accepts blame as Hamilton laments Ferrari approach
-
Yamal hits double as 'nearly perfect' Barca thrash Valencia
-
Sabalenka surges past Townsend to reach US Open quarter-finals
-
Antonelli living 'a dream' after astonishing home win
-
Smiling face of Germany's far-right AfD: Ulrich Siegmund
-
Impressive Daryz keeps Arc double dream alive
-
Lebanon president calls for US help as Israeli strikes kill 7
-
Strasbourg hit Troyes for six as Amo-Ameyaw sparkles
-
Yamal hits double as perfect Barca thrash Valencia
-
German far-right AfD landslide winner in eastern state vote
-
Venice festival turns gaze on war reporters, media industry
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Watch the "What This Means" video here
IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of severe deep Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company is currently performing the final testing necessary to seek IDE approval from the FDA to begin the U.S. pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
Y.Nakamura--AMWN
